ArticleDiscover oncology2026
Pan-cancer multi-omics dissection of podosome-related genes reveals their dual roles in tumor invasion and immune modulation.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPodosomes and their cancer-specific counterparts, invadopodia, are pivotal organelles facilitating extracellular matrix (ECM) degradation and tumor invasion. However, the pan-cancer landscape and clinical implications of podosome-related genes (PRGs) remain largely unexplored.
methodsWe conducted a systematic pan-cancer analysis of six core PRGs—MMP9, NCK1, RHOA, SH3PXD2A, SRC, and STIM1—across 33 tumor types utilizing multi-dimensional datasets from TCGA, GTEx, GDSC, TIDE, and CancerSEA. We integrated expression profiles with somatic mutations, DNA methylation, and copy number variations (CNV) to delineate their regulatory landscape. A podosome activity score was constructed via ssGSEA, and single-cell RNA-seq (scRNA-seq) data were leveraged to resolve cell-type specificity. We further evaluated associations with immune checkpoints, tumor-infiltrating lymphocytes (TILs), and immunotherapy response predictors. Finally, Colon Adenocarcinoma (COAD) was selected for integrative transcriptomic analysis and experimental validation of the hub gene MMP9.
resultsOur analysis revealed that PRGs are extensively dysregulated across tumor types, driven by distinct epigenetic and genomic alterations. Elevated podosome scores correlated with advanced tumor stage, poor prognosis, and an immunosuppressive microenvironment characterized by high TGFB1 expression and T-cell exclusion. Single-cell profiling identified that podosome activity was predominantly enriched in monocytes, endothelial cells, and mast cells, highlighting their role in immune remodeling and angiogenesis. Functionally, PRGs were strongly associated with epithelial–mesenchymal transition (EMT), metastasis, and drug sensitivity, particularly to targeted agents like dasatinib. In COAD, integrated network analysis and in vitro assays confirmed MMP9 as a central driver promoting cancer cell migration and invasion.
conclusionsThis study provides the first comprehensive pan-cancer functional atlas of PRGs. Our findings elucidate the dual roles of PRGs in driving tumor invasion and modulating the immune microenvironment, nominating them as promising biomarkers and therapeutic targets for precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.